Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: Implications for multicellular resistance to alkylating agents

Molecular Cancer Therapeutics

Volumn 4, Issue 10, 2005, Pages 1484-1494

  Francia, Giulio ^a   Green, Shane K ^a   Bocci, Guido ^a   Man, Shan ^a   Emmenegger, Urban ^a   Ebos, John M L ^a   Weinerman, Adina ^a   Shaked, Yuval ^a   Kerbel, Robert S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; DNA; HYALURONIDASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL KILLING; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; DRUG SENSITIZATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MISMATCH REPAIR; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; TUMOR CELL; TUMOR SPHEROID;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZACITIDINE; BASE PAIR MISMATCH; BLOTTING, WESTERN; CARRIER PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA METHYLATION; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXAMIC ACIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 27644547797     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0214     Document Type: Article

References (37)

1. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
2. Kobayashi H, Man S, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993;90:3294-8.
3. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-6.
4. Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anti-Cancer Drug Design 1999;14:153-68.
5. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990;247:1457-61.
6. St.Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst 1996;88: 1285-96.
7. Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-10.
8. Kip1. J Cell Biol 1998;142:557-71.
9. Green SK, Francia G, Isidoro C, Kerbel RS. Anti-adhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004;3:149-59.
10. Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 2004; 24:6837-49.
11. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993;362:652-4.
12. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001;291:1284-9.
13. Fritzell JA, Narayanan L, Baker SM, et al. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 1997;57:5143-7.
14. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997;3:1763-7.
15. Momparler RL, Cote S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 1997;11:175-80.
16. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:2441-52.
17. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6: 3719-28.
18. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS. Rapid acquisition of multicellular drug resistance after a single transient exposure of mammary tumor cells to alkylating agents. J Natl Cancer Inst 1994;86:975-82.
19. Kerbel RS, Rak J, Kobayashi H, Man MS, St.Croix B, Graham CH. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb Symp Quant Biol 1994; 59:661-72.
20. Man S, Bocci G, Francia G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
21. Klunder I, Hulser DF. β-Galactosidase activity in transfected Ltk-cells is differentially regulated in monolayer and in spheroid cultures. Exp Cell Res 1993;207:155-62.
22. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
23. Prolla TA, Baker SM, Harris AC, et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 1998;18:276-9.
24. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996;271:19645-8.
25. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997;15:45-52.
26. Mihaylova VT, Bindra RS, Yuan J, et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003;23:3265-73.
27. Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
28. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
29. Rak J, Mitsuhashi Y, Erdos V, Huang S-N, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by expression of a mutant c-H-ras oncogene. J Cell Biol 1995;131:1587-98.
30. Tomlinson I, Halford S, Aaltonen L, Hawkins N, Ward R. Does MSI-low exist? J Pathol 2002;197:6-13.
31. Halford SE, Sawyer EJ, Lambros MB, et al. MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol 2003;201:389-94.
32. Youn CK, Cho HJ, Kim SH, et al. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol 2005;7:137-47.
33. Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004;24:8504-18.
34. Chan AT, Tao Q, Robertson KD, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004; 22:1373-81.
35. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60:6039-44.
36. Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 1998;18:1635-41.
37. Parsons R, Li GM, Longley M, et al. Mismatch repair deficiency in phenotypically normal human cells. Science 1995;268:738-40.